All In Biotech

NDA 216142 · Baxter Hlthcare Corp

Micafungin In Sodium Chloride 0.9%

Micafungin Sodium · Intravenous

Last checked: Nov 19, 2026Latest source record: Sep 29, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2023

Sep 29, 2023

Approved uses

1

Original approval plus efficacy supplements

Registered trials

58

16 Phase 3, 0 recruiting

FAERS reports

2

1 serious, 0 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Sep 29, 2023.

Micafungin in Sodium Chloride Injection is indicated for: • Treatment of Candidemia, Acute Disseminated Candidiasis, Candida Peritonitis and Abscesses in adult and pediatric patients 4 months of age and older for whom appropriate dosing with this formulation can be achieved [ see Clinical Studies (14.1) and Use in Specific Populations (8.4) ]. • Treatment of Candidemia, Acute Disseminated Candidiasis, Candida Peritonitis and Abscesses without meningoencephalitis and/or ocular dissemination in pediatric patients younger than 4 months of age for whom appropriate dosing with this formulation can be achieved [ see Use in Specific Populations (8.4) ]. • Treatment of Esophageal Candidiasis in adult and pediatric patients 4 months of age and older for whom appropriate dosing with this formulation can be achieved [ see Clinical Studies (14.2) ]. • Prophylaxis of Candida Infections in adult and pediatric patients 4 months of age and older undergoing hematopoietic stem cell transplantation for whom appropriate dosing with this formulation can be achieved [ see Clinical Studies (14.3) ]. Limitations of Use • The safety and effectiveness of Micafungin in Sodium Chloride Injection have not been established for the treatment of candidemia with meningoencephalitis and/or ocular dissemination in pediatric patients younger than 4 months of age as a higher dose may be needed [ see Use in Specific Populations (8.4) ]. • Micafungin in Sodium Chloride Injection has not been adequately studied in patients with endocarditis, osteomyelitis and meningoencephalitis due to Candida. • The efficacy of Micafungin in Sodium Chloride Injection against infections caused by fungi other than Candida has not been established. Micafungin in Sodium Chloride Injection is an echinocandin indicated in adult...

Mechanism: Micafungin is a member of the echinocandin class of antifungal agents [ see Microbiology (12.4) ].

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Sep 29, 2023 Original approval · Type 5 - New Formulation or New Manufacturer LetterLabelReview
3 products under this application
  • MICAFUNGIN IN SODIUM CHLORIDE 0.9% · MICAFUNGIN SODIUM EQ 150MG BASE/150ML (EQ 1MG BASE/ML) · SOLUTION, INTRAVENOUS · Prescription
  • MICAFUNGIN IN SODIUM CHLORIDE 0.9% · MICAFUNGIN SODIUM EQ 50MG BASE/50ML (EQ 1MG BASE/ML) · SOLUTION, INTRAVENOUS · Prescription
  • MICAFUNGIN IN SODIUM CHLORIDE 0.9% · MICAFUNGIN SODIUM EQ 100MG BASE/100ML (EQ 1MG BASE/ML) · SOLUTION, INTRAVENOUS · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Micafungin" as an intervention, any sponsor and status, largest first.

All 58 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • no adverse event1
  • taste disorder1

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20262

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 130 on PubMed

Sponsor: Baxter Hlthcare Corp

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.